RT Journal Article
T1 Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry.
A1 De Luca, Giuseppe
A1 Cercek, Miha
A1 Okkels Jensen, Lisette
A1 Bushljetikj, Oliver
A1 Calmac, Lucian
A1 Johnson, Tom
A1 Gracida Blancas, Montserrat
A1 Ganyukov, Vladimir
A1 Wojakowski, Wojtek
A1 von Birgelen, Clemens
A1 IJsselmuiden, Alexander
A1 Tuccillo, Bernardo
A1 Versaci, Francesco
A1 Ten Berg, Jurrien
A1 Laine, Mika
A1 Berkout, Tim
A1 Casella, Gianni
A1 Kala, Petr
A1 López Ledesma, Bernabé
A1 Becerra, Victor
A1 Padalino, Roberto
A1 Santucci, Andrea
A1 Carrillo, Xavier
A1 Scoccia, Alessandra
A1 Amoroso, Giovanni
A1 Lux, Arpad
A1 Kovarnik, Tomas
A1 Davlouros, Periklis
A1 Gabrielli, Gabriele
A1 Flores Rios, Xacobe
A1 Bakraceski, Nikola
A1 Levesque, Sébastien
A1 Guiducci, Vincenzo
A1 Kidawa, Michał
A1 Marinucci, Lucia
A1 Zilio, Filippo
A1 Galasso, Gennaro
A1 Fabris, Enrico
A1 Menichelli, Maurizio
A1 Manzo, Stephane
A1 Caiazzo, Gianluca
A1 Moreu, Jose
A1 Sanchis Forés, Juan
A1 Donazzan, Luca
A1 Vignali, Luigi
A1 Teles, Rui
A1 Agostoni, Pierfrancesco
A1 Bosa Ojeda, Francisco
A1 Lehtola, Heidi
A1 Camacho-Freiere, Santiago
A1 Kraaijeveld, Adriaan
A1 Antti, Ylitalo
A1 Visconti, Gabriella
A1 Lozano Martínez-Luengas, Iñigo
A1 Scheller, Bruno
A1 Alexopulos, Dimitrios
A1 Moreno, Raul
A1 Kedhi, Elvin
A1 Uccello, Giuseppe
A1 Faurie, Benjamin
A1 Gutierrez Barrios, Alejandro
A1 Scotto Di Uccio, Fortunato
A1 Wilbert, Bor
A1 Cortese, Giuliana
A1 Dirksen, Maurits T
A1 Parodi, Guido
A1 Verdoia, Monica
K1 COVID-19
K1 Mortality
K1 Percutaneous coronary intervention
K1 Renin-Angiotensin System inhibitors
K1 ST-segment elevation myocardial infarction
AB Concerns have been raised on a potential interaction between renin-angiotensin system inhibitors (RASI) and the susceptibility to coronavirus disease 2019 (COVID-19). No data have been so far reported on the prognostic impact of RASI in patients suffering from ST-elevation myocardial infarction (STEMI) during COVID-19 pandemic, which was the aim of the present study. STEMI patients treated with primary percutaneous coronary intervention (PPCI) and enrolled in the ISACS-STEMI COVID-19 registry were included in the present sub-analysis and divided according to RASI therapy at admission. Our population is represented by 6095 patients, of whom 3654 admitted in 2019 and 2441 in 2020. No difference in the prevalence of SARSCoV2 infection was observed according to RASI therapy at admission (2.5% vs 2.1%, p = 0.5), which was associated with a significantly lower mortality (adjusted OR [95% CI]=0.68 [0.51-0.90], P = 0.006), confirmed in the analysis restricted to 2020 (adjusted OR [95% CI]=0.5[0.33-0.74], P = 0.001). Among the 5388 patients in whom data on in-hospital medication were available, in-hospital RASI therapy was associated with a significantly lower mortality (2.1% vs 16.7%, OR [95% CI]=0.11 [0.084-0.14], p  This is the first study to investigate the impact of RASI therapy on the prognosis and SARSCoV2 infection of STEMI patients undergoing PPCI during the COVID-19 pandemic. Both pre-admission and in-hospital RASI were associated with lower mortality. Among SARSCoV2-positive patients, both chronic and in-hospital RASI therapy showed no impact on survival.
YR 2021
FD 2021-03-16
LK http://hdl.handle.net/10668/17370
UL http://hdl.handle.net/10668/17370
LA en
DS RISalud
RD Apr 6, 2025